血管肽酶抑制剂的研究与开发  

Research and Development of Vasopeptidase Inhibitors

作　　者：黄哲[1] 王礼琛[1] 

机构地区：[1]中国药科大学有机教研室,江苏南京210038

出　　处：《药学进展》2004年第5期214-217,共4页Progress in Pharmaceutical Sciences

摘　　要：血管肽酶抑制剂 (VPIs)能同时抑制血管紧张素转化酶和中性肽链内切酶 ,从而抑制肾素 血管紧张素 醛固酮系统和钠利尿肽的降解 ,促进血管舒张和尿钠排泄 ,发挥降低血压和改善心肾功能的作用。综述VPIs的作用机制及其产品用于高血压和充血性心衰的开发现状。Vasopeptidase inhibitors(VPIs)show a dual inhibition of angiotensin-converting enzyme and neutral endopeptidase, and thus reduce the activity of the rennin-angiotensin-aldosterone system and the degradation of natriuretic peptides, potentiate the vasodilation and natriuresis, lower blood pressure and improve cardionephric function. The acting mechanism and development of VPIs for treatment of hypertension and congestive heart failure were reviewed.

关 键 词：血管肽酶抑制剂 肾素 血管紧张素 醛固酮 高血压 充血性心力衰竭 

分 类 号：R972[医药卫生—药品]